Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin DerivativesPosted by On




CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatmen



Source link

Business

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.